Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (13347)	1/15/1998 12:28:00 PM
From: eddie r gammon	Read Replies (2) \| Respond to of 32384

Hope so, but regardless, LGND will get there someday(g) erg

To: Henry Niman who wrote (13347)	1/15/1998 12:35:00 PM
From: John Zwiener	Read Replies (1) \| Respond to of 32384

Hi Henry, in regards to the heavy trading with LDAKA, there is a news release. biz.yahoo.com Do you know these financers? What is their track record when it comes to the shareholders? Also it seems like a lot for them to be putting up just to get voting control. They must know more about the results. Anyway, it seems that this group may get contol of LDAKA, so what does that mean? I have put ligand into the writing is on the wall group. Longterm looks inevitable.

To: Henry Niman who wrote (13347)	1/15/1998 12:37:00 PM
From: Roy Glen	Read Replies (1) \| Respond to of 32384

Henry, I am interested in the discussion you were having with Andrew and V1 about whether or not retinoids can be effective treatments for solid tumors. Given that one of the main advantages of the retinoids is their low toxicity, would it not make sense to pair them with a cancer vaccine? Biomira has reported very encouraging phase 11 results against breast cancer with a carbohydrate cancer vaccine that also has low toxicity. Even if the pair only matched the effectiveness of chemotherapy, the quality of life benefits would be huge. I am sure other companies are working in the same area. Any thoughts?